XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Cancer Channel
subscribe to Cancer newsletter

Latest Research : Cancer

   DISCUSS   |   EMAIL   |   PRINT
Luma Spectroscopy-Based Cervical Imaging System to be Reviewed by FDA
Apr 19, 2005, 12:37, Reviewed by: Dr.

Luma performs a 12-second scan, during which three optical measures � native evoked fluorescence, diffuse reflectance backscatter and video imaging � are employed to detect potential precancerous lesions on the cervix.

 
MediSpectra will present data from a 2,200-woman trial with its Luma spectroscopy-based cervical imaging system at FDA�s Obstetrics & Gynecology Devices Panel meeting on May 17.

The clinical trial, started in 2002, studied women with abnormal Pap smears and compared the performance of Luma as an adjunct to colposcopy against colpo�scopy alone. Colposcopy, currently the gold standard, is a visual examination of the cervix using a large, electric microscope.


Luma performs a 12-second scan, during which three optical measures � native evoked fluorescence, diffuse reflectance backscatter and video imaging � are employed to detect potential precancerous lesions on the cervix.

The three measurements are refined and quantified further through multivariate analysis to provide tissue distinctions. Final results are displayed on a monitor as a false-color map that represents the cervix based on areas of disease probability.

MediSpectra claims a major advantage of the device is that it is not dependent on the expertise of the operator.

The Lexington, Mass. firm�s 604-patient pilot study showed that Luma detected 31% more high-grade precancerous lesions than colposcopy alone. The company has predicted the device eventually could replace colposcopy as the gold standard.

If approved, Luma would be the first spectroscopy-based imaging device for cervical cancer detection. In July, the firm was granted expedited PMA review by FDA.

However, MediSpectra is not alone in its efforts to market a cervical cancer detection device. SpectRx is working on a non-invasive detector and University of Texas at Austin is developing a spectroscopy device for precancerous cervical cells.

Australian firm Polartechnics offers a technology similar to Luma, but it is used as an adjunct to Pap smear and is only available in Australia and Italy.

The ob/gyn panel will also hear a presentation by the Center for Devices & Radiological Health�s Office of Surveillance & Biometrics �outlining their responsibility for the review of postmarket study design,� FDA notes.
 

- FDA�s Obstetrics & Gynecology Devices Panel
 

www.fdaadvisorycommitte.com

 
Subscribe to Cancer Newsletter
E-mail Address:

 

This meeting will be held May 17, 2005 at the Holiday Inn in Gaithersburg, Md. beginning at 8:30 a.m.

Related Cancer News

Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis
Breast cancer chemotherapy may deterioration in cognitive function
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening
Genomic signatures to guide the use of chemotherapeutics
Elderly Breast Cancer Patients May Be Under-Diagnosed And Under-Treated
Listening to the sound of skin cancer
Tissue Geometry Plays Crucial Role in Breast Cell Invasion
Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
CDK2/FOXO1 as drug target to Prevent Tumors
Key to lung cancer chemotherapy resistance revealed


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us